why choose us

First received: February 24, 2023

Clinical Trial: Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: NSCLC, Stage III

Study Type: INTERVENTIONAL


Official Title: Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab in Patients With Inoperable Stage III Non-small Cell Lung Cancer: The Indiana Trial

Brief Summary: This research aims to incorporate ctDNA analysis into clinical practice to individualize therapy in patients with stage III NSCLC by moving to a treatment-by-marker based approach (as opposed to treatment based on clinical or radiographic evidence of disease).

Read more